- Home
- EYPT vs ORIC Comparison
EYPT vs ORIC Comparison
Compare EYPT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- ORIC
- Stock Information
- Founded
- EYPT 1987
- ORIC 2014
- Country
- EYPT United States
- ORIC United States
- Employees
- EYPT N/A
- ORIC N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- EYPT Industrials
- ORIC Health Care
- Exchange
- EYPT Nasdaq
- ORIC Nasdaq
- Market Cap
- EYPT 967.4M
- ORIC 1.1B
- IPO Year
- EYPT 2005
- ORIC 2020
- Fundamental
- Price
- EYPT $14.50
- ORIC $11.75
- Analyst Decision
- EYPT Strong Buy
- ORIC Strong Buy
- Analyst Count
- EYPT 5
- ORIC 11
- Target Price
- EYPT $29.60
- ORIC $18.78
- AVG Volume (30 Days)
- EYPT 1.4M
- ORIC 1.1M
- Earning Date
- EYPT 11-05-2025
- ORIC 11-13-2025
- Dividend Yield
- EYPT N/A
- ORIC N/A
- EPS Growth
- EYPT N/A
- ORIC N/A
- EPS
- EYPT N/A
- ORIC N/A
- Revenue
- EYPT $42,339,000.00
- ORIC N/A
- Revenue This Year
- EYPT N/A
- ORIC N/A
- Revenue Next Year
- EYPT N/A
- ORIC N/A
- P/E Ratio
- EYPT N/A
- ORIC N/A
- Revenue Growth
- EYPT N/A
- ORIC N/A
- 52 Week Low
- EYPT $3.91
- ORIC $3.90
- 52 Week High
- EYPT $14.91
- ORIC $14.93
- Technical
- Relative Strength Index (RSI)
- EYPT 65.45
- ORIC 41.22
- Support Level
- EYPT $13.43
- ORIC $11.02
- Resistance Level
- EYPT $14.67
- ORIC $12.50
- Average True Range (ATR)
- EYPT 0.91
- ORIC 0.83
- MACD
- EYPT 0.32
- ORIC -0.12
- Stochastic Oscillator
- EYPT 99.54
- ORIC 22.22
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.